TABLE 2.
Vaccination protocols and post-vaccination COVID-19
| Overall (n=1071) | Responders (n=173) | Non-responders (n=898) | p-value | |
| Vaccine manufacturer | 0.14 | |||
| BNT162b2 (Pfizer-BioNTech) | 777 (73) | 118 (68) | 659 (73) | |
| mRNA-1273 (Moderna) | 145 (13) | 28 (16) | 117 (13) | |
| ChAdOx1 nCoV-19 (AstraZeneca) | 16 (1) | 0 | 16 (2) | |
| Combined mRNA | 6 (1) | 2 (1) | 4 (0) | |
| Combined mRNA and AstraZeneca | 127 (12) | 25 (15) | 102 (12) | |
| Times to serology (months) | ||||
| Time from lung transplantation to first vaccine dose | 64 (30–110) | 96 (56–156) | 57 (26–104) | 0.002 |
| Time from third vaccination dose to serology | 3.0 (1.7–4.1) | 3.3 (2.1–4.1) | 2.8 (1.6–4.1) | 0.034 |
| Intervals between vaccine doses (days) | ||||
| First to second | 27 (27–30) | 27 (24–30) | 30 (27–31) | 0.18 |
| Second to third | 43 (30–64) | 46 (30–70) | 43 (30–61) | 0.10 |
| Type of immunoassay | 0.005 | |||
| Abbott | 635 (59) | 69 (40) | 566 (63) | |
| DiaSorin | 207 (19) | 52 (33) | 155 (17) | |
| Elecsys | 96 (9) | 6 (5) | 90 (10) | |
| Cerba | 75 (7) | 23 (12) | 52 (6) | |
| Roche Diagnostics | 43 (4) | 11 (7) | 32 (4) | |
| NovaTec | 15 (2) | 12 (3) | 3 (0) | |
| COVID-19 after vaccination | 51 (5) | 4 (2) | 47 (5) | 0.12 |
| Moderate | 36 (3) | 4 (2) | 32 (4) | 0.40 |
| Severe | 8 (1) | 0 | 8 (1) | 0.71 |
| Critical | 7 (1) | 0 | 7 (1) | 0.83 |
| Deaths due to COVID-19 | 6 (1) | 0 | 6 (1) | 0.99 |
| Curative monoclonal antibodies | 13 (1) | 1 (1) | 12 (1) | 0.99 |
| Time from third vaccine dose to COVID-19 (months) | 6.6 (5.1–7.3) | 7.1 (6.6–7.4) | 6.4 (4.9–7.3) | 0.33 |
Data are presented as n (%) or median (interquartile range), unless otherwise stated.